New
HealthMore in Health→
Apitegromab Preserves Lean Mass During Tirzepatide Weight Loss in Phase 2 Trial
A phase 2 trial shows apitegromab, a myostatin inhibitor, preserves lean mass during tirzepatide-induced weight loss, reducing lean mass loss by 54.9% versus placebo.
Key Takeaways
- Apitegromab reduced lean mass loss by 1.9 kg vs placebo (54.9% retention) during tirzepatide weight loss.
- Total weight loss was similar between groups, showing selective lean mass preservation.
DE
DT Editorial Team··via nature.com